Compare Travere Therapeutics Inc. Common Stock (TVTX) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs UnitedHealth Group Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B), while UnitedHealth Group Inc trades at $397.69 (market cap $355.11B). The key difference: UnitedHealth Group Inc is far larger — about 70.7× Travere Therapeutics Inc. Common Stock's market cap, and UnitedHealth Group Inc pays a 2.35% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and UnitedHealth Group Inc for 98 Days on average.
| TVTX | UNH | |
|---|---|---|
Market Cap | $5.02B | $355.11B |
Volume | 2,060,842 | 7,759,080 |
Sector | Health | Health |
52-Week High | $67.52 | $436.35 |
52-Week Low | $26.79 | $259.02 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $5.15B | $396.97B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
UnitedHealth Group (UNH) trades at $377.76, down 0.2% on the day, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $6.38 surpassing the $4.91 expectation. Revenue reached $447.57 billion in 2025, though net income margin declined to 2.69%. Recent news highlights dividend payments and strategic moves like the TPG deal for WellMed clinics.
UNH presents a favorable outlook with a consensus price target of $470.11, implying significant upside. Strengths include robust cash flow, a dominant market position, and AI investments in Optum. Risks involve regulatory pressures, rising medical costs, and debt levels. The stock remains a core holding for growth-oriented investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
